Nitric Oxide Synthase Type II
"Nitric Oxide Synthase Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CALCIUM-independent subtype of nitric oxide synthase that may play a role in immune function. It is an inducible enzyme whose expression is transcriptionally regulated by a variety of CYTOKINES.
| Descriptor ID |
D052247
|
| MeSH Number(s) |
D08.811.682.664.500.772.500 D12.776.157.687.575 D12.776.660.720.575
|
| Concept/Terms |
Nitric Oxide Synthase Type II- Nitric Oxide Synthase Type II
- Inducible NOS Protein
- NOS-II
- NOS II
- Nitric Oxide Synthase II
- Nitric Oxide Synthase, Type II
- Inducible Nitric Oxide Synthase
- INOS Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Nitric Oxide Synthase Type II".
Below are MeSH descriptors whose meaning is more specific than "Nitric Oxide Synthase Type II".
This graph shows the total number of publications written about "Nitric Oxide Synthase Type II" by people in this website by year, and whether "Nitric Oxide Synthase Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 7 | 7 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 5 | 5 |
| 2005 | 2 | 6 | 8 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 4 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitric Oxide Synthase Type II" by people in Profiles.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Non-viral nitric oxide-based gene therapy improves perfusion and liposomal doxorubicin sonopermeation in neuroblastoma models. Theranostics. 2023; 13(10):3402-3418.
-
DNA-based fluorescent probes of NOS2 activity in live brains. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):14694-14702.
-
Anti-rheumatoid arthritis effects of flavonoids from Daphne genkwa. Int Immunopharmacol. 2020 Jun; 83:106384.
-
Soybean-derived recombinant human epidermal growth factor protects against experimental necrotizing enterocolitis. J Pediatr Surg. 2018 Jun; 53(6):1203-1207.
-
IL-17A induces heterogeneous macrophages, and it does not alter the effects of lipopolysaccharides on macrophage activation in the skin of mice. Sci Rep. 2017 09 29; 7(1):12473.
-
Oxidative stress: a key regulator of leiomyoma cell survival. Fertil Steril. 2017 06; 107(6):1387-1394.e1.
-
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Cancer Chemother Pharmacol. 2016 Mar; 77(3):549-58.
-
SET7/9 Enzyme Regulates Cytokine-induced Expression of Inducible Nitric-oxide Synthase through Methylation of Lysine 4 at Histone 3 in the Islet ß Cell. J Biol Chem. 2015 Jul 03; 290(27):16607-18.
-
Monocytes and infection: modulator, messenger and effector. Immunobiology. 2015 Feb; 220(2):210-4.